Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
1.
Acta méd. peru ; 40(1)ene. 2023.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1439129

RESUMO

El cavernoma cerebral es una malformación vascular de diagnóstico infrecuente. Se define como una malformación a nivel de la vasculatura microcerebral que, dependiendo a la ubicación y si existe la posibilidad de ruptura, conlleva a una emergencia que puede terminar en la muerte del paciente. En esta oportunidad se reporta el caso de un paciente con cavernoma cerebral asociado al síndrome de Evans. Se decide manejo quirúrgico de la lesión por aumento de intensidad de cefalea e intolerancia oral. Dada la coexistencia del Síndrome de Evans y la alta tasa de morbimortalidad es que se decide manejo quirúrgico mediante radiocirugía estereotáxica con gamma knife. El uso de dosis de margen bajo para tratamiento con gamma knife para uso en cavernomas cerebrales produce un manejo controlado para sintomatología de convulsiones y mejor expectativa de calidad de vida.


Cerebral cavernoma is an infrequently diagnosed vascular malformation. It is defined as a malformation at the level of the microcerebral vasculature that, depending on the location and if there is a possibility of rupture, leads to an emergency that can end in the death of the patient. On this occasion, we report a case of a patient with cerebral cavernoma associated with Evans syndrome. Surgical management of the lesion was decided due to increased intensity of headache and oral intolerance. Given the coexistence of Evans Syndrome and the high rate of morbidity and mortality, surgical management was decided by stereotaxic radiosurgery with a gamma knife. The use of low-margin doses for treatment with gamma knife for use in brain cavernomas produces controlled management for seizure symptoms and better quality of life expectancy.

2.
Chinese Journal of Internal Medicine ; (12): 147-155, 2023.
Artigo em Chinês | WPRIM | ID: wpr-994394

RESUMO

Objective:We sought to investigate the clinical characteristics and risk factors of antiphospholipid syndrome (APS) complicated by autoimmune hemolytic anemia (AIHA).Methods:Retrospective anaysis.Three hundred fifteen consecutive patients with APS were enrolled at the Department of Rheumatology of Peking Union Medical College Hospital between May 2017 to May 2021, and their clinical manifestations[including initial symptoms, time interval between APS onset and diagnosis, systemic lupus erythematosus(SLE), thrombotic events, obstetric morbidity, and extra-criteria manifestations] and laboratory test results[including blood routine, antiphospholipid antibodies(aPLs), blood lipid profile, homocysteine, anti-nuclear antibody profile, immunoglobulin levels, and complement levels] were collected. Then, univariate and multivariate logistic regression analyses were performed. Clinical features and risk factors were analyzed using univariable and multivariable logistic regression analysis.Results:Among 315 APS patients, 37 cases (11.7%) were complicated by AIHA, and AIHA was the first manifestation or co-occurrence. The median time interval between APS onset and diagnosis was 12 months. The proportion of SLE in APS patients combined with AIHA was higher than that in APS patients without AIHA[62.2%(23/37) vs. 19.4%(54/278), P<0.001]. There was no significant difference in the proportions of thrombosis and pregnancy morbidity between the two groups. In terms of extra-criteria manifestations, APS patients with AIHA had a significantly ( P<0.05) greater risk of thrombocytopenia ( OR=6.19, 95% CI 2.81-13.65) and higher proportions of hypocomplementemia, a positive lupus anticoagulant (LA) result, double aPLs positivity[i.e., any two of the following antibodies were positive: LA, anticardilolipin antibody(aCL), and anti-β2 glycoprotein Ⅰ(β2GPⅠ)], and triple aPLs positivity (i.e., LA, aCL, and anti-β2GPⅠ antibodies were all positive). Multivariate logistic regression analysis showed that SLE ( OR=3.46,95% CI 1.60-7.48), thrombocytopenia ( OR=2.56,95% CI 1.15-5.67), and hypocomplementemia ( OR=4.29,95% CI 2.03-9.04) were independent risk factors for the complication of APS. In the primary APS subgroup, multivariate logistic regression analysis showed that livedo reticularis ( OR=10.51,95%CI 1.06-103.78), thrombocytopenia ( OR=3.77, 95% CI 1.23-11.57), and hypocomplementemia ( OR=5.92,95% CI 1.95-17.95) were independent risk factors for the complication of APS. Conclusions:AIHA is not rare in APS patients; moreover, it occurs more frequently in APS secondary to SLE and is more likely to present with a variety of extra-criteria manifestations. Patients with AIHA should be promptly tested for antiphospholipid antibody profiles and alerted to the possibility of thrombotic events.

4.
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1381651

RESUMO

Novos parâmetros hematológicos, como a fração de reticulócitos imaturos (IRF), tendem a se tornar ferramentas importantes na prática clínica. O IRF identifica os reticulócitos mais imaturos, que contêm grande quantidade de ácido ribonucleico, sendo um importante parâmetro para avaliar a atividade da medula óssea, em tempo real, para o diagnóstico diferencial das anemias, acompanhamento do seu tratamento, e para o acompanhamento ou recuperação da medula óssea em diversas condições clínicas. No entanto, ainda há um longo caminho a percorrer antes que a IRF possa ser usada na prática clínica. Assim sendo, é urgente estabelecer os valores de referência e padronizar as metodologias utilizadas pelos diferentes analisadores hematológicos e como expressar seus resultados. Esta revisão narrativa fornece uma perspectiva crítica sobre o IRF e seu potencial para o uso clínico, bem como suas limitações.


New hematological parameters, such as immature reticulocyte fraction (IRF), tend to become important tools in clinical practice. IRF identifies the most immature reticulocytes that contain a large amount of ribonucleic acid, being an important parameter to evaluate bone marrow activity in real time for differential diagnosis of anemias, monitoring of its treatment, and for follow-up or bone marrow recovery in various clinical conditions. However, there is still a long way to go before IRF can be used in clinical practice. Thus, it is urgent to establish reference values and to standardize of the methodologies used by different hematological analyzers and how to express the results. This narrative review provides a critical perspective on IRF, its potential of clinical use and limitations.

5.
Arch. med ; 21(1): 165-181, 2021/01/03.
Artigo em Espanhol | LILACS | ID: biblio-1148442

RESUMO

Introducción: la anemia es un problema de salud pública en países desarrollados y no desarrollados; esta entidad tiene repercusiones en el desarrollo socioeconómico de las comunidades y, especialmente, en la salud de embarazadas, niños y jóvenes. Objetivo: describir los aspectos generales del síndrome anémico, sus presentaciones más frecuentes y el estado del arte de dicha problemática en el suroccidente colombiano. Método: se realizó una búsqueda bibliográfica con un lapso de 30 años (1990-2020) en Medline, Google Scholar, Lilacs y Redalyc, para revisar los conceptos generales del síndrome anémico, anemia por déficit de hierro, anemia megaloblástica, anemia hemolítica y anemia de células falciformes, en función de la etiología, epidemiología, manifestaciones clínicas, diagnóstico y pronóstico. Resultados: el síndrome anémico es una entidad frecuente en varias regiones de Colombia, con alta carga epidemiológica, complicaciones y pronóstico importantes. Se realizó la descripción general de las presentaciones más frecuentes del síndrome anémico. Conclusión: hacen falta estudios para todas las regiones del país, particularmente, en el suroccidente colombiano..Au


Introduction: anemia is a public health problem both in developed and undeveloped countries; this entity has repercussions in socioeconomic development of communities and, especially, compromises pregnant women, children and young people health. Objective: to describe the general aspects of anemia syndrome, its most frequent presentations and the state of the art of this problem in southwestern Colombia. Methods: a literature search with a span of 30 years (1990-2020) was performed in Medline, Google Scholar, Lilacs and Redalyc databases, in order to describe the general concepts of anemic syndrome, iron deficiency anemia, megaloblastic anemia, hemolytic anemia and sickle cell anemia, regarding on its etiology, epidemiology, clinical manifestations, diagnosis and prognosis. Results: anemic syndrome is a frequent entity in several Colombian regions, with high epidemiological burden, complications and important prognoses. The general description of the most frequent presentations of anemia syndrome was made. Conclusion: additional studies are required for each region, particularly in southwestern Colombia..Au


Assuntos
Humanos , Anemia
6.
Journal of Clinical Hepatology ; (12): 2320-2323, 2021.
Artigo em Chinês | WPRIM | ID: wpr-904940

RESUMO

Objective To investigate the influencing factors for ribavirin (RBV)-induced hemolytic anemia in the treatment of chronic hepatitis C, and to provide a reference for the early prediction of ribavirin-related hemolytic anemia in clinical practice. Methods A total of 49 patients with chronic hepatitis C who attended or were hospitalized in Hebei Petrochina Central Hospital from January 2018 to July 2019 and received antiviral therapy with direct-acting antiviral agent (DAA) and RBV were enrolled, with a major allele of C allele and a minor allele of A allele at the rs1127354 locus of the inosine triphosphate pyrophosphatase (ITPA) gene, and the patients with AA and AC genotypes were compared with those with CC genotype. During treatment, RBV was reduced to 600 mg when hemoglobin (Hb) level was < 100 g/L and was withdrawn when Hb level was < 85 g/L. Routine blood test, liver function, liver stiffness measurement, HCV RNA, HCV genotype, and ITPA genotype were measured before antiviral therapy, and the routine blood test was performed at weeks 2, 4, 8, and 12 of treatment. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. Results A total of 49 patients were enrolled in this study, among whom 22 had chronic hepatitis C and 27 had liver cirrhosis, with a sustained virologic response (SVR) rate of 95.9%. The dose of RBV was reduced in 3 patients (2 in the AA/AC group and 1 in the CC group) due to anemia, and RBV was withdrawn in 3 patients (1 in the AA/AC group and 2 in the CC group); all these 6 patients had liver cirrhosis and finally achieved SVR. During the anti-HCV therapy with DAA+RBV, there was relatively mild RBV-related hemolysis, and the maximum reduction in Hb from baseline was compared between the patients with AA/AC genotype at ITPA rs1127354 and those with CC genotype, which showed no significant difference between the two groups ( Z =-0.18, P =0.87). Conclusion During the treatment with RBV+DAA, RBV is withdrawn or reduced for liver cirrhosis patients due to anemia, and no obvious statistical relation is observed between ITPA genotype and the maximum reduction in Hb from baseline. Therefore, detection of ITPA genotype before the application of RBV does not improve safety during treatment, and it is not recommended to perform conventional detection of ITPA gene polymorphisms.

7.
Journal of Clinical Hepatology ; (12): 2320-2323, 2021.
Artigo em Chinês | WPRIM | ID: wpr-904890

RESUMO

Objective To investigate the influencing factors for ribavirin (RBV)-induced hemolytic anemia in the treatment of chronic hepatitis C, and to provide a reference for the early prediction of ribavirin-related hemolytic anemia in clinical practice. Methods A total of 49 patients with chronic hepatitis C who attended or were hospitalized in Hebei Petrochina Central Hospital from January 2018 to July 2019 and received antiviral therapy with direct-acting antiviral agent (DAA) and RBV were enrolled, with a major allele of C allele and a minor allele of A allele at the rs1127354 locus of the inosine triphosphate pyrophosphatase (ITPA) gene, and the patients with AA and AC genotypes were compared with those with CC genotype. During treatment, RBV was reduced to 600 mg when hemoglobin (Hb) level was < 100 g/L and was withdrawn when Hb level was < 85 g/L. Routine blood test, liver function, liver stiffness measurement, HCV RNA, HCV genotype, and ITPA genotype were measured before antiviral therapy, and the routine blood test was performed at weeks 2, 4, 8, and 12 of treatment. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. Results A total of 49 patients were enrolled in this study, among whom 22 had chronic hepatitis C and 27 had liver cirrhosis, with a sustained virologic response (SVR) rate of 95.9%. The dose of RBV was reduced in 3 patients (2 in the AA/AC group and 1 in the CC group) due to anemia, and RBV was withdrawn in 3 patients (1 in the AA/AC group and 2 in the CC group); all these 6 patients had liver cirrhosis and finally achieved SVR. During the anti-HCV therapy with DAA+RBV, there was relatively mild RBV-related hemolysis, and the maximum reduction in Hb from baseline was compared between the patients with AA/AC genotype at ITPA rs1127354 and those with CC genotype, which showed no significant difference between the two groups ( Z =-0.18, P =0.87). Conclusion During the treatment with RBV+DAA, RBV is withdrawn or reduced for liver cirrhosis patients due to anemia, and no obvious statistical relation is observed between ITPA genotype and the maximum reduction in Hb from baseline. Therefore, detection of ITPA genotype before the application of RBV does not improve safety during treatment, and it is not recommended to perform conventional detection of ITPA gene polymorphisms.

8.
Journal of Leukemia & Lymphoma ; (12): 735-738, 2021.
Artigo em Chinês | WPRIM | ID: wpr-929720

RESUMO

Objective:To explore the efficacy of rituximab combined with ABVD (epirubicin+ bleomycin+ vindesine +dacarbazine) regimen in treatment of Hodgkin lymphoma (HL) complicated with autoimmune hemolytic anemia (AIHA).Methods:The clinical data of 1 HL patient complicated with AIHA in November 2019 in Henan Cancer Hospital were retrospectively analyzed, and literatures were reviewed.Results:The patient received left cervical lymph node biopsy and bone marrow biopsy, and then lymphoma-related gene mutations and whole genetic genome detection were performed. The patient was diagnosed as HL (tuberous sclerosis in stage Ⅳ) complicated with AIHA. After 6 cycles of rituximab combined with ABVD regimen, the efficacy was evaluated. This patient's anemia was recovered, and HL also achieved complete remission.Conclusions:Rituximab combined with ABVD regimen is effective in treatment of HL patients complicated with AIHA.

9.
Rev. méd. Chile ; 147(7): 836-841, jul. 2019. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1058612

RESUMO

Background: Autoimmune hemolytic anemia (AIHA) is an uncommon disease. In its presentation, it can be severe and even lethal. There is only one clinical report concerning this pathology in Chile. Objective: To describe the clinical characteristics and evolution of adult AIHA inpatients. Materials and Methods: Retrospective review of clinical records of adult AIHA inpatients between January 2010 and June 2018 was done. Demographic, clinical, laboratory and therapeutic information was analyzed. A descriptive, analytical and survival analysis was performed. Results: Forty-three adult patients diagnosed with AHIA were hospitalized in a period of 8 years. Median age was 63 years (range 22-86 years), mostly women (72%). Warm antibodies were detected in 36 cases (84%) and cold antibodies in seven. Seventy two percent of the patients had an underlying cause, and 58% were secondary to lymphoproliferative neoplasms. All patients except two, received steroids as initial treatment, with response in 37 (90%) of them. Three refractory patients received rituximab, with response in all of them, and relapse in one. Median follow-up was 38 months (range 2-98 months). Five year overall survival was 72%. Conclusion: AHIA in adults inpatients is a heterogeneous disease, mainly due to warm antibodies, and to secondary etiology.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Anemia Hemolítica Autoimune/diagnóstico , Esplenectomia , Azatioprina/administração & dosagem , Análise de Sobrevida , Estudos Retrospectivos , Seguimentos , Rituximab/administração & dosagem , Anemia Hemolítica Autoimune/mortalidade , Anemia Hemolítica Autoimune/terapia
10.
Chinese Journal of Perinatal Medicine ; (12): 289-295, 2019.
Artigo em Chinês | WPRIM | ID: wpr-756110

RESUMO

Objective To investigate the outcomes of fetuses with hemolytic anemia caused by red cell alloimmunization following intrauterine transfusion (IUT),and to analyze the influence of hydrops fetalis on IUT treatment.Methods A retrospective analysis was conducted on 70 fetuses,who were admitted to the Fetal Medicine Center,the First Affiliated Hospital of Sun Yat-sen University from January 2005 to May 2018,with hemolytic disease requiring IUT.Clinical data of the fetuses and the gravidas were collected and divided into hydrops group (17 cases) and non-hydrops group (53 cases) based on their conditions before IUT.Results of routine blood tests before and after the first IUT,gestational age at the first IUT,prognosis and outcomes of the fetuses were compared between two groups.t-test,rank-sum test,Chi-square test (or Fisher's exact test) and multivariant logistic regression analysis were used for data analysis.Results Totally,the 70 fetuses underwent 231 times of IUT.Compared with the non-hydrops group,the hydrops group had a significantly increased incidence of severe anemia [14/17 vs 47.2% (25/53),x2=6.458,P=0.011],but decreased hemoglobin [(38.5 ± 21.4) vs (68.7± 19.3) g/L,t=5.471,P<0.001] and hematocrit level [0.110 (0.044-0.246) vs 0.222 (0.077-0.299),Z=-4.390,P<0.001] before the first IUT.After the IUT,the survival rate of the fetuses in hydrops group was significantly lower than that of the non-hydrops group [11/15 vs 94.3% (50/53),P=0.038].There was no significant difference in gestational age at birth,birth weight,neonatal hemoglobin level at birth,the incidence of exchange transfusion,the number of blood transfusions required or the incidence of severe neonatal complication between the two groups (all P>0.05).Logistic regression analysis indicated that the fetal hydrops was an independent risk factor for fetal survival (OR=12.8,95%CI:1.2-136.4,P=0.035).Conclusions Hydrops fetalis might reduce the survival rate of fetal hemolytic disease after 1UT.

11.
Rev. méd. Chile ; 146(11): 1347-1350, nov. 2018.
Artigo em Espanhol | LILACS | ID: biblio-985709

RESUMO

Sickle cell anemia was a rare disease in Chile, especially in adults, however the recent immigration wave from Haiti is changing this scenario. We report a 29 year old black female from Haiti with a non-disclosed history of sickle cell anemia. She was transfused with two units of red blood cells, found unconscious and with jaundice five days later and admitted to the hospital. On admission she had a hemoglobin of 3.3 g/dL, a total bilirubin of 5.08 mg/dL, a LDH of 1,306 Ui/L. She was transfused again, worsening her condition. An alloimmunization and delayed hemolytic reaction was suspected. A direct Coombs test was positive. She was treated with steroids and her serum hemoglobin rose progressively.


Assuntos
Humanos , Feminino , Adulto , Transfusão de Eritrócitos/efeitos adversos , Reação Transfusional/etiologia , Anemia Falciforme/terapia , Chile , Resultado do Tratamento , Reação Transfusional/terapia , Haiti/etnologia , Anemia Falciforme/complicações , Anemia Falciforme/etnologia
12.
J. Bras. Patol. Med. Lab. (Online) ; 54(4): 255-259, July-Aug. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-954402

RESUMO

ABSTRACT Thrombocytopenic thrombotic purpura (TTP) is a severe hemorrhagic syndrome characterized by thrombocytopenia, microangiopathic hemolytic anemia and microvascular occlusion, besides the associated symptoms that may or may not be present: fever, neurological and renal impairment. The pathophysiology involves the autoimmune or genetic deficiency of a metalloproteinases activity (ADAMTS-13), responsible for the von Willebrand Factor cleavage. The treatment is based on plasmapheresis; and in acute or recurrent cases, corticosteroids and immunosuppressants are associated. In this article, we will discuss a case report about this disease, initially treated in the Emergency Room and followed in the Intensive Care Unit of a public reference hospital in São Paulo city, Brazil. All clinical diagnostic criteria were completely filled, facilitating the therapeutic approach of the patient. The report evidences that rapid intervention when made early diagnosis evolves with a good prognosis, and this pathology must be present as a differential diagnosis in the medical routine.


RESUMO Púrpura trombocitopênica trombótica (PTT) é uma síndrome hemorrágica grave caracterizada por trombocitopenia, anemia hemolítica microangiopática e oclusão microvascular, bem como por sintomas associados que podem ou não estar presentes, como febre, comprometimento neurológico variável e comprometimento renal. A fisiopatologia implicada na doença envolve a deficiência, seja por inibição autoimune ou defeito genético, seja pela atividade de uma metaloproteinase (ADAMTS-13), responsável pela clivagem de multímeros do fator de von Willebrand (FvW). O tratamento consiste na plasmaférese e, em casos agudos graves ou recorrentes, associa-se a corticoterapia e imunossupressores. Neste artigo, abordaremos um relato de caso sobre essa doença, cuja paciente foi atendida inicialmente em pronto-socorro, sendo em seguida internada em uma unidade de terapia intensiva (UTI) de um hospital público de referência da cidade de São Paulo, Brasil. Todos os critérios clínicos diagnósticos foram completamente preenchidos, facilitando a abordagem terapêutica da paciente. O relato evidencia que a rápida intervenção, quando se faz o diagnóstico precoce, evolui com bom prognóstico, devendo esta patologia estar presente como diagnóstico diferencial no cotidiano médico.

13.
Rev. bras. cir. cardiovasc ; 33(1): 107-109, Jan.-Feb. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-897985

RESUMO

Abstract A significant prosthetic paravalvular leak is an uncommon and severe postsurgical complication correlated to the occurrence of congestive heart failure and hemolytic anemia. Percutaneous treatment has become an attractive and effective proposal to relieve symptoms and reduce complications in patients whose high rate of morbidity/mortality precludes a new surgery. This is the case of an 81-year-old patient with a history of biological aortic valve replacement seeking medical help due to heart failure and hemolytic anemia, with a prosthetic paravalvular regurgitation jet and high surgical mortality according to EuroSCORE II.


Assuntos
Humanos , Masculino , Idoso de 80 Anos ou mais , Bioprótese/efeitos adversos , Próteses Valvulares Cardíacas/efeitos adversos , Embolização Terapêutica/instrumentação , Dispositivo para Oclusão Septal , Insuficiência Cardíaca/terapia , Ecocardiografia Transesofagiana , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/etiologia
14.
Rev. bras. oftalmol ; 77(1): 50-53, jan.-fev. 2018. graf
Artigo em Português | LILACS | ID: biblio-899106

RESUMO

Resumo Relatar um caso de paciente com Retinopatia vaso-oclusiva por Lúpus Eritematoso Sistêmico (LES) associado à Síndrome do Anticorpo Antifosfolipídeo (SAF), que se iniciou com um quadro de anemia hemolítica autoimune acompanhado por baixa visual súbita monocular. Poucos casos foram descritos na literatura nacional e mundial em que o LES se manifeste primeiramente com alterações oculares. O screening dos Anticorpos antifosfolípideos (APAs) é de suma importância para pacientes com retinopatia lúpica para que seja instituída a terapia imediata com anticoagulantes como forma de prevenir a trombose vascular, o que piora o prognóstico visual.


Abstract To report the case of a patient with vaso-occlusive retinopathy due to systemic lupus erythematosus (SLE) associated with antiphospholipid antibody syndrome (APAS), which started with signs and symptoms of autoimune hemolytic anemia accompanied by sudden monocular visual loss. Few cases of SLE manifestation primarily involving ocular changes have been reported in the Brazilian and international literature. Screening for antiphospholipid antibodies is of the greatest importance for patients with lupus retinopathy, so that immediate therapy with anticoagulants may be instituted in order to prevent vascular thrombosis, which worsens the visual prognosis.


Assuntos
Humanos , Feminino , Adulto , Oclusão da Veia Retiniana/etiologia , Síndrome Antifosfolipídica/complicações , Lúpus Eritematoso Sistêmico/complicações , Oftalmoscopia , Retina/diagnóstico por imagem , Varfarina/uso terapêutico , Oclusão da Veia Retiniana/diagnóstico , Oclusão da Veia Retiniana/terapia , Metilprednisolona/uso terapêutico , Prednisona/uso terapêutico , Hemorragia Retiniana/diagnóstico , Triancinolona/uso terapêutico , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/terapia , Pulsoterapia , Tomografia de Coerência Óptica , Injeções Intraoculares , Hidroxicloroquina/uso terapêutico , Anemia Hemolítica Autoimune/tratamento farmacológico , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/terapia
15.
Tianjin Medical Journal ; (12): 654-656, 2018.
Artigo em Chinês | WPRIM | ID: wpr-698087

RESUMO

Hemolytic diseases of newborn (HDN) can cause miscarriage, premature birth, fetal edema, fetal intrauterine anemia and even fetal death in early pregnancy. Neonatus with HDN can have jaundice, anemia, hepatosplenomegaly, edema and nuclear jaundice sequelae. This article reviewed the diagnosis and treatment of two patients with HDN caused by anti-E and anti-Ec combined with anti-Fyb, and reviewed the relevant literature on the epidemilogy, the diagnosis and treatment of HDN in order to improve the understanding of the disease.

16.
Chinese Journal of Internal Medicine ; (12): 656-660, 2018.
Artigo em Chinês | WPRIM | ID: wpr-710091

RESUMO

Objective To investigate the significant of peripheral CD4+CD69+T lymphocytes in patients with autoimmune hemolytic anemia (AIHA)/Evans syndrome (ES).Methods In this study peripheral blood samples from 32 patients with AIHA/ES (15 hemolytic episode patients,17 remission patients) and 13 healthy controls were collected.Patients with AIHA/ES were recruited in Tianjin Medical University General Hospital from October 2015 to May 2016.The percentages of CD69+ T lymphocytes were analyzed by flow cytometry.The expression of CD69 mRNA in CD4+T lymphocytes which was sorted from peripheral blood by magnetic activated cell sorting (MACS) was detected using real-time PCR.Soluable CD69 was measured by ELISA.Results In hemolytic episode patients,the ratio of CD3+CD69+/CD3+T lymphocytes [(3.08 ± 1.48)%] was significantly higher than that in healthy controls [(1.28 ± 0.83)%,P<0.01] and in remission group[(1.96± 1.33)%,P<0.05].The absolute count of CD3+CD69+T lymphocytes in hemolytic episode group [(2.94± 1.81)× 107/L] was higher than that in healthy controls [(1.48± 1.42)× 107/L,P<0.05].The ratio of CD3+CD4+CD69+/CD3+CD4+T cells in hemolytic episode group [(2.16± 1.56)%] was significantly higher than that in remission group [(1.16±0.62)%,P<0.05] and healthy controls[(0.94±0.78)%,P<0.05].The quantity of CD3+CD4+CD69+T lymphocytes in hemolytic episode group[(1.04±0.98)× 107/L] was higher than in healthy controls [(0.44± 0.38) × 107 / L,P<0.05].The ratio of CD3+CD8+CD69+/CD3+ CD8+T lymphocyte in hemolytic episode group [(4.87±2.56)%] was significantly higher than that in healthy controls[(1.83± 1.27)%,P<0.01].The quantity of CD3+CDs+CD69+T lymphocytes in three groups did not show significant difference.The ratio of CD3+CD4+CD69+/CD3+CD4+T lymphocytes in hemolytic episode group was negatively correlated with hemoglobin (Hb) (P<0.01),positively correlated with the percentage of reticulocytes (Ret%)(P=0.01)total bilirubin(TBil),indirect bilirubin(IBil) (P<0.01) and not correlated with absolute reticulocytes count,lactic dehydrogenase (LDH),complement 3(C3),complement 4 (C4).The ratio of CD3+CD4+CD69+/CD3+CD4+T lymphocytes in remission group was negatively correlated with Hb (P<0.05).In hemolytic episode patients CD69 mRNA (32.26±35.11) was significantly higher than that in remission group(6.05±5.87)(P<0.05)and healthy controls (1.76± 1.85)(P<0.01).CD69 mRNA in remission group was significantly higher than healthy controls (P<0.05).Serum CD69 in hemolytic episode patients [(494.21 ± 16.06) ng/L] was significantly higher than that in healthy controls [(441.39± 104.6) ng/L,P<0.05].Conclusion Our findings suggest that the proportion of CD4+CD69+ T lymphocytes increase in AIHA/ES patients,which is correlated with the severity of disease.

17.
Chinese Journal of Pediatrics ; (12): 48-52, 2018.
Artigo em Chinês | WPRIM | ID: wpr-809766

RESUMO

Objective@#To investigate the clinical features and genetic characteristics of cases with X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN).@*Methods@#Characteristics of clinical material, immunological data and gene mutation of two cases with XMEN in the same family in China were retrospectively analyzed. The related reports literature were searched by using search terms'MAGT1 gene’or'XMEN’.@*Results@#The proband, a 2-year-eight-month old boy, was admitted due to 'Urine with deepened color for two days and yellow stained skin for one day’. He had suffered from recurrent upper respiratory tract infection and sinusitis previously. Hemoglobin level was 38 g/L. The absolute count of reticulocytes was 223.2×109/L. Urobilinogen level was 38 μmol/L (3-16 μmol/L). Coomb's test was positive. Both total (77.2 μmol/L) and indirect bilirubin (66 μmol/L) levels were elevated. There was an inverted CD4+/CD8+T cell ratio (0.89). The gene sequencing results showed MAGT1 gene c.472delG, p.D158Mfs*6 mutation. His 1-year-6-month old brother, was also identified to have MAGT1 gene c.472delG, p.D158Mfs*6 mutation.The younger brother mainly suffered from recurrent upper respiratory tract infection, accompanied by an inverted CD4+/CD8+T cell ratio (0.45), an elevated ratio and number of total B cells (45.7%). A total of 7 reports were retrieved including 11 male cases caused by MAGT1 gene mutation. These 11 cases were characterized by EBV viremia (11 cases), recurrent upper respiratory tract infection, otitis media or sinusitis (10 cases), secondary neoplasia diseases (8 cases), reduction of CD4+/CD8+ T cell ratio (7 cases),and autoimmune thrombocytopenia or hemolytic anemia (2 cases).@*Conclusion@#XMEN often manifests as male onset, recurrent upper respiratory tract infection, otitis media or sinusitis, EBV viremia, lymphoproliferative disease or lymphoma, autoimmune diseases and reduction of CD4+/CD8 +T cell ratio. NKG2D expression in NK cells is significantly reduced, and gene sequencing analysis shows a pathogenic mutation in MAGT1 gene.

18.
Journal of Leukemia & Lymphoma ; (12): 573-576, 2018.
Artigo em Chinês | WPRIM | ID: wpr-691673

RESUMO

Autoimmune hemolytic anemia (AIHA) is a common complication of chronic lymphocytic leukemia (CLL) with a complicated pathogenesis. CLL tumor cells can trigger AIHA by directly secreting autoantibodies targeting red blood cells or by presenting erythrocyte antigens. According to the disease features of different patients, multiple treatment regimens, such as glucocorticoid, immunoglobulin, rituximab and chemotherapy containing rituximab and glucocorticoid, could be chosen. AIHA patients respond well to the treatment, but it is easy to relapse. Further studies are needed to optimize the treatment and improve the overall survival of the patients.

19.
Journal of Leukemia & Lymphoma ; (12): 228-233,237, 2018.
Artigo em Chinês | WPRIM | ID: wpr-806469

RESUMO

Objective@#To summarize the clinical characteristics and treatment experiences of autoimmune hemolytic anemia (AIHA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).@*Methods@#The clinical data of the patient with AIHA after allogeneic HSCT in Hematology Department of the First Affiliated Hospital of Soochow University was analyzed, and the literatures were reviewed.@*Results@#After receiving 2 years of allo-HSCT, one young male patient with severe aplastic anemia showed AIHA in the absence of obvious incentives. The patient healed with the treatments of glucocorticoid, intravenous injection of gamma globulin, plasma exchange combined with injection of CD20 monoclonal antibody. Through the literature review, it showed that AIHA patients after HSCT had a good response to regimens containing rituximab, while adult and malignant patients with post-HSCT AIHA had a higher mortality. Poor response to rituximab was one of the greatest risk factors for poor prognosis.@*Conclusion@#AIHA is not sensitive to hormone with a low treatment response, which is a risk factor for the increased mortality of allo-HSCT patients.

20.
MedUNAB ; 20(3): 374-382, 2018.
Artigo em Espanhol | LILACS | ID: biblio-965155

RESUMO

Introducción: La anemia falciforme es una hemoglobinopatía estructural de origen genético, se caracteriza por la presencia de hemoglobina falciforme. La hemoglobina anormal es inestable, tiende a polimerizarse y puede ocluir la microcirculación, produciendo manifestaciones multisistémicas tanto agudas como crónicas relacionándose con mayor riesgo de contraer infecciones. Objetivo: Describir la información del tema expuesto resaltando los aspectos más relevantes como diagnóstico y tratamiento. Metodología: Se efectuó una revisión bibliográfica con búsqueda electrónica en las siguientes bases de datos: PubMed, MEDLINE, Medscape, Scopus; y se incluyó diferentes tipos de artículo (artículos originales, revisiones de temas y guías de manejo) que abordaran la anemia de células falciformes en pediatría. Resultados: Se obtuvo una revisión de 22 artículos, donde se describe el tema de anemia de células falciformes, pautas y tratamientos basados en el manejo y control de los síntomas; se evidencia que el uso de ecografía doppler transcraneal y las transfusiones demostraron ser estrategias preventivas o de tratamiento eficaces para las complicaciones relacionadas con esta patología en los niños. Conclusiones: En Colombia, la prevalencia de la patología no se encuentra establecida. Por otra parte, las principales manifestaciones se relacionan con complicaciones de vaso-oclusión en los diferentes órganos y la asplenia funcional, la cual predispone a cuadros infecciosos.[Tirado-Pérez IS, Zárate Vergara AC. Anemia de células falciformes en pediatría: Revisión de la literatura. Revisión de tema. MedUNAB 2017-2018; 20(3): 374-382].


Introduction: Sickle cell anemia is a structural hemoglobinopathy of genetic origin, characterized by the presence of sickle hemoglobin. Abnormal hemoglobin is unstable and tends to polymerize and can occlude the microcirculation. Also, it produces both acute and chronic multi system manifestations associated with an increased risk of infection. Objective: To describe the information of the exposed topic highlighting the most relevant aspects such as diagnosis and treatment. Methodology: A literature review with electronic search was carried out in the following databases: PubMed, MEDLINE, Medscape, Scopus; different types of articles were included that addressed sickle cell anemia in pediatrics such as original articles, reviews of topics and management. Results:Areview of 22 articles was obtained which describes the subject of sickle cell anemia, guidelines and treatments based on the management and control of symptoms. It is evident that the use of transcranial Doppler ultrasound and transfusions proved to be preventive strategies or effective treatments for the complications related to this pathology in children. Conclusions: In Colombia, the prevalence of the pathology is not established yet. On the other hand, the main manifestations are related to complications of vaso-occlusion in different organs and functional asplenia which predisposes to infectious conditions. [Tirado-Pérez IS, Zárate Vergara AC. Sickle Cell Anemia in Pediatrics: Literature review. MedUNAB 2017-2018; 20(3): 374-382].


Introdução: A anemia falciforme é uma hemoglobinopatia estrutural de origem genética, caracterizada pela presença de hemoglobina falciforme. A hemoglobina anormal é instável, tende a polimerizar-se e pode ocluir a microcirculação, produzindo manifestações multissistêmicas agudas e crônicas, associadas ao risco enorme das infecção graves. Objetivo: Descreva a informação do assunto exposto, destacando os aspectos mais relevantes, como o diagnóstico e seu tratamento. Metodologia: Foi realizada uma pesquisa eletrônica para a revisão bibliográfica, nos seguintes bancos de dados: PubMed, MEDLINE, Medscape, Scopus; incluindo outros tipos de artigos (artigos originais, revisões de tópicos e guias de gerenciamento), que abordam anemia falciforme em pediatria. Resultados: Foi obtida uma revisão de 22 artigos, que descreve o assunto da anemia falciforme, diretrizes e orientações baseados no tratamento e controle dos síntomas. É evidente que a identificação da doença com o uso de ultrasom Doppler transcraniana e das transfusões são estratégias preventivas ou de tratamentos eficazes para as complicações relacionadas com esta patologia nas crianças. Conclusões: Na Colômbia, a prevalência da patologia não está estabelecida. Por outro lado, as principais manifestações estão relacionadas a complicações de vaso-oclusão em diferentes órgãos e asplenia funcional, que predispõe a condições infecciosas. [Tirado-Pérez IS, Zárate Vergara AC. Anemia falciforme em pediatria: Revisão da literatura. MedUNAB 2017-2018; 20(3): 374-382].


Assuntos
Anemia Falciforme , Pediatria , Hemoglobina Falciforme , Doença da Hemoglobina SC , Anemia Hemolítica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA